Mind Medicine (MindMed) (NASDAQ: MNMD)
Mind Medicine (MindMed) Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mind Medicine (MindMed) Company Info
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.
News & Analysis
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
Why Mind Medicine Zoomed 8% Higher on Tuesday
The support for legalizing drugs -- such as those being studied by the company -- grows with a U.S. senator's tweet.
Why Mind Medicine Stock Triumphed on Tuesday
The company is going back into the lab, and investors are eager to see what it discovers.
Why Mind Medicine Stock Soared on a Down Day for the Market
A highly dilutive new round of financing is making the stock behave like a yo-yo.
Why Mind Medicine (MindMed) Stock Is Crashing Today
The maker of psychedelic drugs announced the pricing of its latest public offering.
Wall Street Says This Stock Can Deliver a 543% Return. Should You Listen?
Find out why investment bank analysts think this stock is positioned for a six-fold gain.
Why Mind Medicine (MindMed) Stock Tumbled This Week
MindMed's stock has been moving lower ever since its reverse split last month.
This Meme Stock Just Did a Huge Reverse Stock Split
Is Mind Medicine a buy?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.